|
Philip J. Young joined Osteologix as President and CEO in May 2007. Prior to joining the company he has held a number of senior executive positions with public biotech companies, most recently from 2004 - 2007 with Insmed Inc., where Mr. Young served as Executive Vice President and Chief Business Officer. While at Insmed, Mr. Young led the successful launch and commercialization of a novel biologic growth therapy and expanded a European Named Patient Program. Prior to joining Insmed, Mr. Young served as President and Chief Operating Officer for AGY Therapeutics and Chief Executive Officer of GanTech International. From 1998-2000, Mr. Young was Vice President and General Manager of Neurex Pharmaceuticals, where he was responsible for developing and managing the commercial and clinical strategies for new product launches and expanding label indications. Prior to Neurex, Mr. Young was Business Director and General Manager of the Peptide Hormones Division at Pharmacia (Pfizer) where under his leadership strategies were developed which led to the successful launch of Genotropin for pediatric and adult growth hormone deficiency. Mr. Young also served for seven years at Genentech where he was the Product Manager of Growth Hormone Products. | 